Radiosynthesis and in vivo evaluation of a new positron emission tomography radiotracer targeting bromodomain and extra-terminal domain (BET) family proteins.
Bromodomain
Epigenetic
Imaging
PET
Radiotracer
Journal
Nuclear medicine and biology
ISSN: 1872-9614
Titre abrégé: Nucl Med Biol
Pays: United States
ID NLM: 9304420
Informations de publication
Date de publication:
Historique:
received:
22
01
2020
revised:
02
04
2020
accepted:
07
04
2020
pubmed:
23
4
2020
medline:
14
7
2021
entrez:
23
4
2020
Statut:
ppublish
Résumé
Bromodomain and extra-terminal domain (BET) family proteins play a vital role in the epigenetic regulation process by interacting with acetylated lysine (Ac-K) residues in histones. BET inhibitors have become promising candidates to treat various diseases through the inhibition of the interaction between BET bromodomains and Ac-K of histone tails. With a molecular imaging probe, noninvasive imaging such as positron emission tomography (PET) can visualize the distribution and roles of BET family proteins in vivo and enlighten our understanding of BET protein function in both healthy and diseased tissue. We radiolabeled the potent BET inhibitor INCB054329 by N-methylation to make [ In our in vitro evaluation, PB003 showed a high BET binding affinity for BRDs (K The imaging results in rodents in vivo demonstrate that [
Identifiants
pubmed: 32320910
pii: S0969-8051(20)30017-2
doi: 10.1016/j.nucmedbio.2020.04.003
pii:
doi:
Substances chimiques
Nuclear Proteins
0
Radioactive Tracers
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
96-101Subventions
Organisme : NIH HHS
ID : S10 OD023517
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS108115
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.